AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

IMUGENE LTD

0.035

-0.001-2.78%

Volume:7.26M

Turnover:254.52K

Market Cap:261.01M

PE:-1.92

High:0.036

Open:0.036

Low:0.035

Close:0.036

Loading ...

Overview Company News Filings

ASX Market Update: Index retreats as Chinese stimulus disappoints | November 11, 2024

The Market Herald

Imugene Doses First Patient in Intratumoral Injection Group of Phase 1 Cancer Trial

MT Newswires Live

Imugene Opens Australian Site for Phase 1b Lymphoma Trial

MT Newswires Live

Why Imugene, Neuren, Sigma, and Smartgroup shares are charging higher

Imugene Says Bile Tract Cancer Patient Remains in Complete Response for Over Two Years in Early-Stage Trial

MT Newswires Live

Why Core Lithium, Imugene, Lifestyle Communities, and Mineral Resources shares are charging higher

Guess which ASX 300 stock is jumping 11% on big news

ASX Market Update: Gina Rinehart buys permits from Min Res in billion dollar deal | October 31, 2024

The Market Herald

2 All Ords ASX healthcare shares making BIG moves on quarterly updates

Why AGL, Imugene, Star, and Woolworths shares are dropping today

Those who invested in Imugene (ASX:IMU) five years ago are up 144%

Simply Wall St.

Australian Shares Hit Fresh 52-Week High Ahead of US Interest Rate Decision; Harvey Norman Faces Class Action

MT Newswires Live

BUZZ-Australia's Imugene hits 2-week high on FDA orphan status for cancer treatment

Imugene Secures US FDA's Orphan Drug Designation for Bile Tract Cancer Treatment Candidate; Shares Rise 4%

MT Newswires Live

BRIEF-Imugene Ltd Says Received US FDA Orphan Drug Designation For Vaxinia

Imugene Ltd - Imugene Receives Orphan Drug Designation for Vaxinia

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IMU.AU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMU.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMU.AU\",,,,,undefined,":{"symbol":"IMU.AU","market":"AU","secType":"STK","nameCN":"IMUGENE LTD","latestPrice":0.035,"timestamp":1741234322274,"preClose":0.036,"halted":0,"volume":7264054,"delay":0,"changeRate":-0.027778,"change":-0.001,"floatShares":6260580705,"shares":7457433979,"eps":-0.018233,"lyrEps":-0.021115,"pbRate":4.12,"amount":254515,"amplitude":0.027778,"volumeRatio":0.518099,"dividePrice":0,"prevYearClose":0.037,"fiveDayClose":0.038,"twentyDayClose":0.036},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMU.AU\",,,,,undefined,":{"symbol":"IMU.AU","floatShares":6260580705,"roa":"-42.92%","roe":"-100.19%","lyrEps":-0.021115,"volumeRatio":0.518099,"shares":7457433979,"dividePrice":0,"high":0.036,"amplitude":0.027778,"preClose":0.036,"low":0.035,"week52Low":0.035,"pbRate":"4.12","psRate":"-94.66","week52High":0.12,"institutionHeld":0,"latestPrice":0.035,"committee":-0.143859,"eps":-0.018233,"divideRate":0,"volume":7264054,"delay":0,"ttmEps":-0.018233,"open":0.036,"prevYearClose":0.037,"prevWeekClose":0.037,"prevMonthClose":0.037,"prevQuarterClose":0.037,"fiveDayClose":0.038,"twentyDayClose":0.036,"sixtyDayClose":0.038},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMU.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMU.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMU.AU\",pageSize:16,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2482249519","title":"ASX Market Update: Index retreats as Chinese stimulus disappoints | November 11, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2482249519","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482249519?lang=en_us&edition=fundamental","pubTime":"2024-11-11 10:34","pubTimestamp":1731292440,"startTime":"0","endTime":"0","summary":"The ASX200 has been down 0.4% at 8,261 points.Investors reacted with disappointment to the latest Chinese stimulus measures released on the weekend. Declining iron ore and oil prices has adversely affected commodity stocks, as hopes of a strong uptick in Chinese driven demand were dashed.Materials has been the worst performer, down 2.4%, followed by Staples, down 1.7% and Energy, down 0.8%.Resoulute Mining  has been down 30% on news its CEO Terry Holohan and other company executives have been detained by the military controlled government of Mali in West Africa.Imugene has been up 4.4% on news its kicked off the injection phase of a trial of its innovative onCARlytics  candidate. This pivotal development marks the dosing of the first patient grappling with advanced solid tumours.Li-S Energy has been up 5.7% on reports it used a twelve-cell lithium sulfur battery pack to power a small UAV for 30 minutes. The fixed wing asset, which doesn’t use quadcopter style propellors and instead was","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-update-index-retreats-as-chinese-stimulus-disappoints-november-11-2024-2024-11-11/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7506","BK7067","RSG.AU","IMU.AU","BK7508","BK7104","LIS.AU","BK7023"],"gpt_icon":0},{"id":"2482221089","title":"Imugene Doses First Patient in Intratumoral Injection Group of Phase 1 Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2482221089","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482221089?lang=en_us&edition=fundamental","pubTime":"2024-11-11 09:42","pubTimestamp":1731289374,"startTime":"0","endTime":"0","summary":"Biotechnology company Imugene  said the first patient was dosed in the intratumoral combination group of phase 1 clinical trial on its oncolytic virotherapy candidate, CD19, according to a Monday filing with the Australian bourse.The study is part of the company's Oasis trial, which aims to evaluate the safety and efficacy of CD19 in patients with advanced or metastatic solid tumors, the filing said. It will explore the direct administration of CD19 into the tumor, as well as intravenous infusion.The trial is being conducted at seven US sites, with the potential to open a total of 10 sites to recruit up to 40 patients, according to the filing.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","IMU.AU","BK7508"],"gpt_icon":0},{"id":"2481711242","title":"Imugene Opens Australian Site for Phase 1b Lymphoma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2481711242","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481711242?lang=en_us&edition=fundamental","pubTime":"2024-11-08 14:49","pubTimestamp":1731048579,"startTime":"0","endTime":"0","summary":"Imugene  opened its first Australian site for a phase 1b trial investigating the use of cell therapy azercabtagene zapreleucel as a potential treatment for patients with relapsed or diffused large-B lymphoma, according to a Friday filing with the Australian bourse.The US portion of the trial showed three patients having a complete response using the therapy, the filing said.Patient recruitment at the Australian site is slated for November, the filing added.The company's shares closed up more than 2% Friday.Price : $0.05, Change: $+0.001, Percent Change: +2.22%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0994945656.USD","IMU.AU","LU0426412945.USD","XAO.AU","XJO.AU","BK4125","XKO.AU","AUD","LU0426417589.USD","BK7067","LU1043141123.HKD","BK7508","LU0345774631.USD","LU2238339852.HKD"],"gpt_icon":0},{"id":"2481873167","title":"Why Imugene, Neuren, Sigma, and Smartgroup shares are charging higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2481873167","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481873167?lang=en_us&edition=fundamental","pubTime":"2024-11-08 10:13","pubTimestamp":1731032010,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index(ASX: XJO) is having a great finish to the week. In afternoon trade, the benchmark index is up 0.9% to 8,299.4 points. Four ASX shares that are rising more than most are listed bel","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/08/why-imugene-neuren-sigma-and-smartgroup-shares-are-charging-higher/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["IMU.AU","XJO.AU","SIQ.AU","BK7508","NEU.AU","BK7096","BK7067","BK7057","SIG.AU","BK7103"],"gpt_icon":0},{"id":"2481698654","title":"Imugene Says Bile Tract Cancer Patient Remains in Complete Response for Over Two Years in Early-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2481698654","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481698654?lang=en_us&edition=fundamental","pubTime":"2024-11-06 09:14","pubTimestamp":1730855648,"startTime":"0","endTime":"0","summary":"Biotechnology company Imugene  said a bile tract cancer patient in its phase 1 metastatic advanced solid tumors trial for Vaxinia, a treatment candidate for bile tract cancer, remained in complete response, surpassing over two years in remission, according to a Tuesday filing with the Australian bourse.Meanwhile, the trial's bile tract cancer expansion phase cleared its first group, with the three patients experiencing no dose-limiting toxicities, and is now open for enrollment of up to 10 patients, the filing said.The company also secured a patent extension to 2040 from the US Patent and Trademark Office for patent application number 16/324,541, protecting its oncolytic virotherapy CF33, including Vaxinia and CHECKVacc, according to the filing.Imugene shares fell past 2% in morning trade Wednesday.Price : $0.05, Change: $-0.001, Percent Change: -2.13%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AUD","LU0426412945.USD","SSI","LU2238339852.HKD","BK7508","BK7067","LU0994945656.USD","LU1043141123.HKD","IMU.AU","LU0345774631.USD","LU0426417589.USD","BK4125"],"gpt_icon":1},{"id":"2481175516","title":"Why Core Lithium, Imugene, Lifestyle Communities, and Mineral Resources shares are charging higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2481175516","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481175516?lang=en_us&edition=fundamental","pubTime":"2024-11-05 11:54","pubTimestamp":1730778848,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index (ASX: XJO) is out of form on Tuesday and dropping into the red. In afternoon trade, the benchmark index is down 0.4% to 8,132.7 points. Four ASX shares that are not letting that h","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/05/why-core-lithium-imugene-lifestyle-communities-and-mineral-resources-shares-are-charging-higher/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7162","BK7062","BK7511","BK7095","IMU.AU","BK7145","BK7005","BK7036","BK7508","RIO.AU","XJO.AU","BK7067","BK7504","CXO.AU","BK7507","LTM.AU","MIN.AU","HMC.AU","LIC.AU"],"gpt_icon":1},{"id":"2481856425","title":"Guess which ASX 300 stock is jumping 11% on big news","url":"https://stock-news.laohu8.com/highlight/detail?id=2481856425","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481856425?lang=en_us&edition=fundamental","pubTime":"2024-11-05 07:28","pubTimestamp":1730762884,"startTime":"0","endTime":"0","summary":"Imugene Ltd  shares are having a strong start to the session on Tuesday. At the time of writing, the ASX 300 stock is up 11% to 4.9 cents. Why is this ASX 300 stock jumping?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/05/guess-which-asx-300-stock-is-jumping-11-on-big-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","IMU.AU","BK7508"],"gpt_icon":0},{"id":"2479482337","title":"ASX Market Update: Gina Rinehart buys permits from Min Res in billion dollar deal | October 31, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2479482337","media":"The Market Herald","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479482337?lang=en_us&edition=fundamental","pubTime":"2024-10-31 11:17","pubTimestamp":1730344620,"startTime":"0","endTime":"0","summary":"The ASX200 has been down a third of a percent  at 8,154 points.Consumer Staples continue to be the worst performing sector, down 1.7%, with well-known plays Woolworths , Bega Cheese  and Elders  all dragging the local bourse lower. Utilities has been 1.2% softer, followed by Industrials, down 1%.IT has been the best performer, up 0.4%, followed by Discretionary, up 0.24% and Real Estate, up 0.15%.Imugene  has been down 4.3% on its quarterlies. The company reported cash or cash equivalents of $54.3 million, down from $93.1 million in the June quarter.Mineral Resources  has been up 11.3% on release of its quarterlies. The company has agreed to sell its two oil and gas exploration permits in the Perth Basin to Gina Rinehart’s Hancock Prospecting. Hancock will pay Mineral Res up to $1.1 billion for the permits.Coles  has been down 1.1% after releasing its quarterlies before market open. The company delivered a 2.9% increase in total sales to $10.54 billion for the three months ended 29 Sep","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-update-gina-rinehart-buys-permits-from-min-res-in-billion-dollar-deal-october-31-2024-2024-10-31/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7040","BK7141","MIN.AU","BK7507","BK7504","BK7095","BK7505","BK7511","BK7067","BK7501","BK7508","BGA.AU","ELD.AU","IMU.AU","COL.AU","BK7117","BK7082","WOW.AU"],"gpt_icon":1},{"id":"2479523715","title":"2 All Ords ASX healthcare shares making BIG moves on quarterly updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2479523715","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479523715?lang=en_us&edition=fundamental","pubTime":"2024-10-31 09:39","pubTimestamp":1730338765,"startTime":"0","endTime":"0","summary":"Paradigm share price lifts off on trial progress The Paradigm Biopharmaceuticals Ltd  share price is up 2.5% at the time of writing, having earlier posted gains of 17.5%. Shares are currently changing hands for 20.5 cents apiece. That leaves the All Ords ASX healthcare share down 51% since this time last year. Investors have been bidding up the Paradigm share price after the company reported on the \"substantial progress\" it made over the quarter in its Phase 3 clinical trial preparations for the treatment of knee osteoarthritis with its iPPS product. Commenting on the recent achievements, Paradigm Biopharmaceuticals managing director Paul Rennie said, \"The submission of our phase 3 protocol to the FDA is a significant milestone for Paradigm.\" Rennie continued:  It represents the culmination of extensive work by our team and close collaboration with the FDA. We are confident that this progress, combined with the anticipated TGA [Therapeutic Goods Administration] response and our ongoing","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/10/31/2-all-ords-asx-healthcare-shares-making-big-moves-on-quarterly-updates/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4220","BK7508","IMU.AU","XAO.AU","XJO.AU","BK7067","PAR.AU","BK4114","BIG"],"gpt_icon":0},{"id":"2479971688","title":"Why AGL, Imugene, Star, and Woolworths shares are dropping today","url":"https://stock-news.laohu8.com/highlight/detail?id=2479971688","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479971688?lang=en_us&edition=fundamental","pubTime":"2024-10-31 09:21","pubTimestamp":1730337685,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index (ASX: XJO) is having another relatively poor session on Thursday. In afternoon trade, the benchmark index is down 0.2% to 8,164.1 points. Four ASX shares that are falling more tha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/10/31/why-agl-imugene-star-and-woolworths-shares-are-dropping-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["WOW.AU","AGL.AU","AGL","BK7508","BK7511","IMU.AU","BK7501","BK7078","BK7136","BK4539","XJO.AU","BK4196","BK7067","SGR.AU","BK7040"],"gpt_icon":0},{"id":"2472555965","title":"Those who invested in Imugene (ASX:IMU) five years ago are up 144%","url":"https://stock-news.laohu8.com/highlight/detail?id=2472555965","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472555965?lang=en_us&edition=fundamental","pubTime":"2024-10-02 07:50","pubTimestamp":1727826609,"startTime":"0","endTime":"0","summary":"It might be of some concern to shareholders to see the Imugene Limited  share price down 19% in the last month. But that scarcely detracts from the really solid long term returns generated by the company over five years. Indeed, the share price is up an impressive 144% in that time. So while it's never fun to see a share price fall, it's important to look at a longer time horizon. Of course, that doesn't necessarily mean it's cheap now. Unfortunately not all shareholders will have held it for five years, so spare a thought for those caught in the 88% decline over the last three years: that's a long time to wait for profits.With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies.ASX:IMU Earnings and Revenue Growth October 1st 2024. There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/those-invested-imugene-asx-imu-235009607.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7067","IMU.AU","BK7508","IMUOE.AU"],"gpt_icon":0},{"id":"2468337877","title":"Australian Shares Hit Fresh 52-Week High Ahead of US Interest Rate Decision; Harvey Norman Faces Class Action","url":"https://stock-news.laohu8.com/highlight/detail?id=2468337877","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468337877?lang=en_us&edition=fundamental","pubTime":"2024-09-18 14:59","pubTimestamp":1726642750,"startTime":"0","endTime":"0","summary":"Australian shares were flat at Wednesday's close but registered a fresh 52-week high for the third straight day as investors braced for expected rate cuts after the US Federal Reserve's monetary polic","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["US7Y.BOND","BK7153","US912797GW17.BOND","BK7067","US30Y.BOND","BK7095","XKO.AU","XAO.AU","IMU.AU","FBM.AU","BK7135","US12M.BOND","XJO.AU","US10Y.BOND","US912797HE00.BOND","BK7508","US6M.BOND","US2Y.BOND","CBA.AU","HVN.AU","US5Y.BOND","BK7041","US3Y.BOND"],"gpt_icon":0},{"id":"2468325433","title":"BUZZ-Australia's Imugene hits 2-week high on FDA orphan status for cancer treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2468325433","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468325433?lang=en_us&edition=fundamental","pubTime":"2024-09-18 12:31","pubTimestamp":1726633862,"startTime":"0","endTime":"0","summary":"**Shares of clinical-stage immune-oncology co Imugene  rise as much as 14.6% to A$0.055; biggest intraday pct gain since Sept. 2   ** U.S. FDA gives orphan drug status to co's VAXINA treatment, aimed at treating cholangiocarcinoma, a form of bile tract cancer   ** FDA grants orphan drug status to promote drug development for rare diseases affecting fewer than 200,000 people in the U.S.    ** Co says orphan status gives it range of incentives including tax credits, potential grant funding and 7-year market exclusivity   ** About 56.7 mln shares change hands vs 30-day avg volume of about 23.7 mln shares   **Stock down 54.5% YTD ","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XAO.AU","IMU.AU","XJO.AU","BK7508","XKO.AU","BK7067"],"gpt_icon":0},{"id":"2468325195","title":"Imugene Secures US FDA's Orphan Drug Designation for Bile Tract Cancer Treatment Candidate; Shares Rise 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2468325195","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468325195?lang=en_us&edition=fundamental","pubTime":"2024-09-18 12:29","pubTimestamp":1726633770,"startTime":"0","endTime":"0","summary":"Imugene  secured an orphan drug designation from the US Food and Drug Administration for Vaxinia, a treatment candidate for bile tract cancer, according to a Wednesday filing with the Australian bourse.The orphan drug designation will allow the drugmaker to receive tax credits, waiver of specific administration fees, and a seven-year market exclusivity for Vaxinia, the filing said.Imugene's shares rose 4% in recent Tuesday trade.Price : $0.05, Change: $+0.0020, Percent Change: +4.17%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","AUD","BK7508","IMU.AU","BK4125"],"gpt_icon":0},{"id":"2468476703","title":"BRIEF-Imugene Ltd Says Received US FDA Orphan Drug Designation For Vaxinia","url":"https://stock-news.laohu8.com/highlight/detail?id=2468476703","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468476703?lang=en_us&edition=fundamental","pubTime":"2024-09-18 11:12","pubTimestamp":1726629137,"startTime":"0","endTime":"0","summary":"Sept 18 (Reuters) - Imugene Ltd   :   * IMUGENE RECEIVES ORPHAN DRUG DESIGNATION FOR VAXINIA   * US FDA GRANTS CF33-HNIS (VAXINIA) ORPHAN DRUG DESIGNATIONFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMU.AU","BK7067"],"gpt_icon":0},{"id":"2468347331","title":"Imugene Ltd - Imugene Receives Orphan Drug Designation for Vaxinia","url":"https://stock-news.laohu8.com/highlight/detail?id=2468347331","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468347331?lang=en_us&edition=fundamental","pubTime":"2024-09-18 11:07","pubTimestamp":1726628829,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240918:nFWN3KZ18Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","IMU.AU","BK7508"],"gpt_icon":0}],"pageSize":16,"totalPage":3,"pageCount":3,"totalSize":48}]}}